124
Participants
Start Date
June 29, 2017
Primary Completion Date
March 27, 2019
Study Completion Date
September 4, 2020
TAF
Tablet administered orally once daily
Chang Gung Medical Foundation, Linkou Chang Gung Memorial Hospital, Taoyuan
Changhua Christian Hospital, Changhua
Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City
Auckland Clinical Studies, Grafton
National Taiwan University Hospital, Taipei
Veterans General Hospital-Taipei, Taipei
U.O. Medicina Generale Epatologia IRCCS Humanitas Centro di Ricerca Traslazionale in Epatologia, Rozzano
UOC Gastroenterol-Epatol.-Fondazione IRCCS Ca Granda, Milan
Dipartimento di Scienze Mediche e Chirurgiche (DIMEC) AOU Policlinico S.Orsola-Malpighi di Bologna, Bologna
Taichung Veterans Genl Hosp, Taichung
Henry Ford Health System, Detroit
Dong-A University Hospital, Busan
Pusan National University Hospital, Busan
Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chiayi City
Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City
Coalition of Inclusive Medicine, Los Angeles
Silicon Valley Research Institute, Inc, San Jose
Harborview Medical Center, Seattle
University of Calgary Liver Unit, Calgary
Centre de Recherche du Centre Hospitalier de l'Universite de Montreal, Montreal
University Health Network,Toronto general Hospital,Toronto centre for liver disease, Toronto
Toronto Liver Centre, Toronto
(G.I.R.I.) GI Research Institute, Vancouver
Prince of Wales Hospital, Shatin
Princess Margaret Hospital, Kowloon
Alice Ho Miu Ling Nethersole Hospital, Tai Po
Asan Medical Center, Seoul
Yonsei University Health System, Severance Hospital, Seoul
Nottingham University Hospital, London
King's College Hospital NHS Foundation Trust, London
Lead Sponsor
Gilead Sciences
INDUSTRY